Pasithea Therapeutics Corp. (KTTA) Reports PAS-004 Tumor Reductions in Phase 1/1b
Pasithea Therapeutics (KTTA) reported positive Phase 1/1b results for PAS-004, showing median 41% reduction in target cNF surface area. All 15 participants had reductions, with deeper reductions at higher doses. FDA cleared Phase 2 trial. No serious adverse events reported. Webcast scheduled for November 13, 2026.
How this was made
The 30-second read
Why it matters
The announcement provides the first public efficacy read‑out, which can move the stock on speculative expectations for a larger Phase 2 trial.
Market read
First disclosure of trial data; potential short‑term price move for KTTA and possible spillover to similar biotech names.
What to watch
No comparator arm and short follow‑up; regulatory approval for Phase 2 does not guarantee success.
Background
Pasithea Therapeutics (KTTA) is a clinical‑stage biotech focused on treatments for neurofibromatosis. The company announced IND clearance and early tumor‑shrinkage data from its ongoing Phase 1/1b trial.
Ticker impact
Pasithea Therapeutics reported Phase 1/1b data showing tumor reductions and FDA IND clearance for Phase 2, a first disclosure of clinical results.
likely modest upside as market prices in the encouraging efficacy signals
The data are preliminary and from a small uncontrolled cohort, so upside is limited but could trigger short‑term buying on biotech risk‑on sentiment.
Market effects
May boost confidence in neurofibromatosis therapeutic pipeline and benefit peer biotech stocks.
Limited to US biotech sector.
Low global impact beyond niche biotech investors.
Counterpoint
Data are from a very small, open‑label study; investors should be cautious of over‑optimism.
Key entities
- companyPasithea Therapeutics Corp.
Clinical‑stage biotech developing PAS‑004 for neurofibromatosis.
